The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development

Gill, Dipender; Zagkos, Loukas; Gill, Rubinder; Benzing, Thomas; Jordan, Jens; Birkenfeld, Andreas L.; Burgess, Stephen; Zahn, Grit

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2024-02-26T11:23:08Z
dc.date.available	2024-02-26T11:23:08Z
dc.date.issued	2023
dc.identifier.issn	1741-7015
dc.identifier.uri	http://hdl.handle.net/10900/151317
dc.language.iso	en	de_DE
dc.publisher	London : Bmc	de_DE
dc.relation.uri	http://dx.doi.org/10.1186/s12916-023-03227-5	de_DE
dc.subject.ddc	610	de_DE
dc.title	The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_00066
utue.personen.roh	Gill, Dipender
utue.personen.roh	Zagkos, Loukas
utue.personen.roh	Gill, Rubinder
utue.personen.roh	Benzing, Thomas
utue.personen.roh	Jordan, Jens
utue.personen.roh	Birkenfeld, Andreas L.
utue.personen.roh	Burgess, Stephen
utue.personen.roh	Zahn, Grit
dcterms.isPartOf.ZSTitelID	Bmc Medicine	de_DE
dcterms.isPartOf.ZS-Issue	Article 504	de_DE
dcterms.isPartOf.ZS-Volume	21 (1)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE